Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0640

0.0%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mammon who wrote (12661)	1/24/2014 2:28:46 PM
From: boomertree2	Read Replies (2) of 13111

See my post 12571 regarding the NEJM discussion of the new BTD, in particular "Since enactment of the FDASIA about 1 year ago, more than 80 requests for a breakthrough-therapy designation have been submitted to the FDA, and 26 have been granted." I hope we get BTD as I have been long since 2005 and have never sold a share. Not every BTD request is granted (historically 32.5% of BTD requests are granted, 67.5% rejected). The fact the Company is filing a BTD Request this quarter is positive, but I can't see this as the clear path to approval that was promised in the Dec PR. Not being negative, just being balanced. I can't cheer for this result, and since the stock is presently trading at $2.29 after hearing the news, the news appears to have also fallen below the market's expectation of a clear FDA path to approval.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next